Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
CHRS's Cash to Debt is ranked higher than
62% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. CHRS: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CHRS' s 10-Year Cash to Debt Range
Min: 9.41  Med: 9999.50 Max: No Debt
Current: No Debt
Equity to Asset 0.39
CHRS's Equity to Asset is ranked lower than
79% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CHRS: 0.39 )
Ranked among companies with meaningful Equity to Asset only.
CHRS' s 10-Year Equity to Asset Range
Min: -2.05  Med: 0.20 Max: 0.39
Current: 0.39
-2.05
0.39
Z-Score: 1.90
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -365.20
CHRS's Operating margin (%) is ranked lower than
68% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. CHRS: -365.20 )
Ranked among companies with meaningful Operating margin (%) only.
CHRS' s 10-Year Operating margin (%) Range
Min: -2028.33  Med: -1308.36 Max: -207.94
Current: -365.2
-2028.33
-207.94
Net-margin (%) -387.67
CHRS's Net-margin (%) is ranked lower than
69% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. CHRS: -387.67 )
Ranked among companies with meaningful Net-margin (%) only.
CHRS' s 10-Year Net-margin (%) Range
Min: -1949.65  Med: -1738.70 Max: -280.12
Current: -387.67
-1949.65
-280.12
ROE (%) -1016.69
CHRS's ROE (%) is ranked lower than
98% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. CHRS: -1016.69 )
Ranked among companies with meaningful ROE (%) only.
CHRS' s 10-Year ROE (%) Range
Min: 0  Med: 0.00 Max: 0
Current: -1016.69
ROA (%) -81.15
CHRS's ROA (%) is ranked lower than
80% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. CHRS: -81.15 )
Ranked among companies with meaningful ROA (%) only.
CHRS' s 10-Year ROA (%) Range
Min: -145  Med: -109.63 Max: -74.26
Current: -81.15
-145
-74.26
ROC (Joel Greenblatt) (%) -3022.20
CHRS's ROC (Joel Greenblatt) (%) is ranked lower than
74% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. CHRS: -3022.20 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CHRS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5546.99  Med: -4113.43 Max: -2679.87
Current: -3022.2
-5546.99
-2679.87
» CHRS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

CHRS Guru Trades in

CHRS Guru Trades in

CHRS Guru Trades in

Q2 2015

CHRS Guru Trades in Q2 2015

Jim Simons 40,907 sh (New)
George Soros 127,600 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with CHRS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 10.00
CHRS's P/B is ranked lower than
83% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. CHRS: 10.00 )
Ranked among companies with meaningful P/B only.
CHRS' s 10-Year P/B Range
Min: 6.35  Med: 13.49 Max: 25.63
Current: 10
6.35
25.63
P/S 5.89
CHRS's P/S is ranked higher than
63% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. CHRS: 5.89 )
Ranked among companies with meaningful P/S only.
CHRS' s 10-Year P/S Range
Min: 1.98  Med: 4.67 Max: 8.45
Current: 5.89
1.98
8.45
Current Ratio 3.43
CHRS's Current Ratio is ranked lower than
57% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. CHRS: 3.43 )
Ranked among companies with meaningful Current Ratio only.
CHRS' s 10-Year Current Ratio Range
Min: 0.85  Med: 2.72 Max: 3.46
Current: 3.43
0.85
3.46
Quick Ratio 3.43
CHRS's Quick Ratio is ranked lower than
54% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. CHRS: 3.43 )
Ranked among companies with meaningful Quick Ratio only.
CHRS' s 10-Year Quick Ratio Range
Min: 0.85  Med: 2.72 Max: 3.46
Current: 3.43
0.85
3.46
Days Sales Outstanding 15.07
CHRS's Days Sales Outstanding is ranked higher than
88% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. CHRS: 15.07 )
Ranked among companies with meaningful Days Sales Outstanding only.
CHRS' s 10-Year Days Sales Outstanding Range
Min: 28.36  Med: 30.37 Max: 36.88
Current: 15.07
28.36
36.88

Valuation & Return

vs
industry
vs
history
Price/Net Cash 19.22
CHRS's Price/Net Cash is ranked lower than
81% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. CHRS: 19.22 )
Ranked among companies with meaningful Price/Net Cash only.
CHRS' s 10-Year Price/Net Cash Range
Min: 18.13  Med: 19.46 Max: 20.79
Current: 19.22
18.13
20.79
Price/Net Current Asset Value 11.77
CHRS's Price/Net Current Asset Value is ranked lower than
71% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 6.84 vs. CHRS: 11.77 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CHRS' s 10-Year Price/Net Current Asset Value Range
Min: 9.22  Med: 12.73 Max: 35.56
Current: 11.77
9.22
35.56
Price/Tangible Book 10.95
CHRS's Price/Tangible Book is ranked lower than
78% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. CHRS: 10.95 )
Ranked among companies with meaningful Price/Tangible Book only.
CHRS' s 10-Year Price/Tangible Book Range
Min: 8.59  Med: 11.84 Max: 29.69
Current: 10.95
8.59
29.69
Price/Median PS Value 1.32
CHRS's Price/Median PS Value is ranked lower than
67% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. CHRS: 1.32 )
Ranked among companies with meaningful Price/Median PS Value only.
CHRS' s 10-Year Price/Median PS Value Range
Min: 0.55  Med: 1.19 Max: 1.45
Current: 1.32
0.55
1.45
Earnings Yield (Greenblatt) (%) -17.97
CHRS's Earnings Yield (Greenblatt) (%) is ranked lower than
70% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. CHRS: -17.97 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CHRS' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -16.82  Med: 0.00 Max: 0
Current: -17.97
-16.82
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
» More Articles for CHRS

Headlines

Articles On GuruFocus.com
A Look at Pharma Company Dermira's Performance Mar 27 2015 

More From Other Websites
Amgen: Time is on My Side Sep 04 2015
Coherus BioSciences to Present at Morgan Stanley Global Healthcare Conference on September 17 Sep 04 2015
Coherus BioSciences to Present at Morgan Stanley Global Healthcare Conference on September 17 Sep 04 2015
Coherus Provides Updates on Clinical Studies Call scheduled for 5:00 pm ET today Sep 03 2015
Coherus Provides Updates on Clinical Studies Sep 03 2015
COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 03 2015
4:04 pm Coherus BioSciences provides update on clinical studies; will increase enrollment in... Sep 03 2015
Coherus Provides Updates on Clinical Studies Sep 03 2015
Lane Bryant Changes The Conversation About Women And Perceptions About Its Brand Sep 02 2015
COHERUS BIOSCIENCES, INC. Financials Aug 21 2015
Edited Transcript of CHRS earnings conference call or presentation 10-Aug-15 8:30pm GMT Aug 11 2015
Coherus BioSciences reports 2Q loss Aug 10 2015
Coherus BioSciences reports 2Q loss Aug 10 2015
Coherus BioSciences Reports Second Quarter 2015 Financial and Operating Results Aug 10 2015
Coherus BioSciences Inc Earnings Call scheduled for 4:30 pm ET today Aug 10 2015
COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change... Aug 10 2015
Coherus BioSciences Reports Second Quarter 2015 Financial and Operating Results Aug 10 2015
Coherus BioSciences to Report Second Quarter 2015 Financial Results on August 10 Jul 28 2015
Coherus BioSciences to Report Second Quarter 2015 Financial Results on August 10 Jul 28 2015
Coherus Biosciences (CHRS) in Focus: Stock Surges 10.7% - Tale of the Tape Jul 13 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK